

# PRIOR AUTHORIZATION CRITERIA

**BRAND NAME\***  
(generic)

**ONFI**  
(clobazam)

**Status: CVS Caremark Criteria**  
**Type: Initial Prior Authorization**

**Ref # 871-A**

\* Drugs that are listed in the target drug box include both brand and generic and all dosages forms and strengths unless otherwise stated

## FDA-APPROVED INDICATIONS

Onfi (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

## COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in a patient 2 years of age or older

## RATIONALE

The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Onfi is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.<sup>1-3</sup>

## REFERENCES

- Onfi [package insert]. Deerfield, IL: Lundbeck Inc.; December 2016.
- Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. [www.micromedexsolutions.com](http://www.micromedexsolutions.com) [available with subscription]. Accessed May 2017.
- AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; [http://online.lexi.com/lco/action/index/dataset/complete\\_ashp](http://online.lexi.com/lco/action/index/dataset/complete_ashp) [available with subscription]. Accessed May 2017.

Written by: UM Development (JK)  
Date Written: 11/2011  
Revised: (CT) 05/2012 (created MDC-1 document); (PL) 10/2012 (extended duration); (MS) 05/2013; (GS/CF) 05/2014; (CF) 05/2015; (MS) 05/2016 (no clinical changes), (JG) 05/2017 (no clinical changes)  
Reviewed: Medical Affairs (KP) 11/2011, (MG) 05/2012; (DC) 05/2013; (LMS) 05/2014; (DNC) 05/2015  
External Review: 12/2011, 06/2012, 10/2013, 10/2014, 10/2015, 10/2016, 07/2017

## CRITERIA FOR APPROVAL

- |   |   |     |    |
|---|---|-----|----|
| 1 | Is the requested drug being prescribed for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in a patient 2 years of age or older? | Yes | No |
|---|---|-----|----|

## Mapping Instructions

	Yes	No	DENIAL REASONS – DO NOT USE FOR MEDICARE PART D
1.	Approve, 36 months	Deny	Your plan covers this drug when you meet all of these conditions: - You are 2 years of age or older - You have seizures associated with Lennox-Gastaut Syndrome - You are taking the requested drug with another seizure drug Your use of this drug does not meet these requirements. This is based on the information we have.